Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Phase 2 Unknown
30 enrolled
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Phase 2 Unknown
73 enrolled
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Phase 2 Unknown
126 enrolled
An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
Phase 2 Unknown
63 enrolled
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Phase 2 Unknown
34 enrolled
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Phase 2 Unknown
93 enrolled 8 charts
NeoTPPF
Phase 2 Unknown
37 enrolled
Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Phase 2 Unknown
61 enrolled
A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
Phase 2 Unknown
120 enrolled
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer
Phase 2 Unknown
46 enrolled
FLIPPER
Phase 2 Unknown
189 enrolled
MEGA
Phase 2 Unknown
20 enrolled
Pyrotinib
Phase 2 Unknown
40 enrolled
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
Phase 2 Unknown
67 enrolled 9 charts
plasmaMATCH
Phase 2 Unknown
1,150 enrolled
FANCY
Phase 2 Unknown
58 enrolled
PALPETBIO
Phase 2 Unknown
54 enrolled
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
Phase 2 Unknown
50 enrolled
FLAG
Phase 2 Unknown
147 enrolled
FRIEND
Phase 2 Unknown
148 enrolled
PROOF
Phase 2 Unknown
180 enrolled
FIDeS
Phase 2 Unknown
104 enrolled